Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Ratio (2020 - 2025)

Cytek Biosciences' Equity Ratio history spans 6 years, with the latest figure at 0.74 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 6.54% year-over-year to 0.74; the TTM value through Dec 2025 reached 0.74, down 6.54%, while the annual FY2025 figure was 0.74, 6.54% down from the prior year.
  • Equity Ratio reached 0.74 in Q4 2025 per CTKB's latest filing, down from 0.76 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.89 in Q3 2021 to a low of 0.05 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.76, with a median of 0.8 recorded in 2023.
  • Peak YoY movement for Equity Ratio: surged 1848.83% in 2022, then dropped 6.54% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.87 in 2021, then fell by 6.38% to 0.82 in 2022, then dropped by 2.96% to 0.79 in 2023, then decreased by 0.34% to 0.79 in 2024, then fell by 6.54% to 0.74 in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Equity Ratio are 0.74 (Q4 2025), 0.76 (Q3 2025), and 0.77 (Q2 2025).